Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Extended-Release Drugs Global Market Report 2025
Request Sample Buy Now
Global Extended-Release Drugs Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Extended-Release Drugs Global Market Report 2025

By Type (Sustained Release Drug, Controlled Release Drug), By Mode (Over-The-Counter, Prescription), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Extended-Release Drugs Market Overview

• Extended-Release Drugs market size has reached to $63.11 billion in 2024

• Expected to grow to $111.26 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%

• Growth Driver: Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market

• Market Trend: Pioneer In Epilepsy Treatment Innovation

• North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Extended-Release Drugs Market?

Extended-release drugs are a dosage form made to release the medication over a longer time, at a predetermined rate, duration, and location, in a controlled manner. The drug can be taken less frequently than the immediate release form, and patients may take 1 to 2 doses each day instead of 3 to 4.

The main types of extended-release drugs are sustained-release drugs and controlled-release drugs. Sustained release drug refers to medication that is intended to slowly release in the body over time, primarily to maintain therapeutic levels. They are available as over-the-counter and prescription modes and distributed by hospital pharmacies, retail pharmacies, mail-order pharmacies, and drug store channels.

Extended-Release Drugs Market Size and growth rate 2025 to 2029: Graph

What Is The Extended-Release Drugs Market Size 2025 And Growth Rate?

The extended-release drugs market size has grown rapidly in recent years. It will grow from $63.11 billion in 2024 to $69.63 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to patient compliance improvement, chronic disease prevalence, improved efficacy, patent protection strategy, biodegradable implants

What Is The Extended-Release Drugs Market Growth Forecast?

The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to $111.26 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to personalized medicine approaches, patient-centric drug development, rising incidence of lifestyle diseases, drug repurposing, global access to extended-release therapies. Major trends in the forecast period include pharmaceutical innovation, advancements in drug delivery systems, advancements in nanotechnology, 3D printing in drug formulations, use of artificial intelligence, environmental sustainability.

The forecast of 12.4% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers may impact U.S. medication adherence by increasing prices of controlled-release polymer matrices and precision coating equipment imported from Switzerland and China, raising chronic disease treatment costs and generic drug production challenges. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Extended-Release Drugs Market Segmented?

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

What Is Driving The Extended-Release Drugs Market? Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market

The increasing incidence of chronic conditions is expected to propel the growth of the extended-release drug market going forward. Chronic conditions are defined as conditions that last for a year or longer and necessitate continuing medical care, restricting everyday activities, or both. Heart disease, cancer, obesity, and diabetes are a few examples. Extended-release drug delivery systems are designed to provide a relatively constant level of medication in the body over a long period. It helps maintain a consistent therapeutic effect and avoids the fluctuations in drug levels that can occur with immediate-release medications. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising to 142.66 million. Therefore, the increasing incidence of chronic conditions is driving the growth of the extended-release drug industry.

What Is Driving The Extended-Release Drugs Market? The Surging Demand For Extended-Release Drugs In Response To Pharmaceutical Industry Growth

The increasing demand for pharmaceutical industry is expected to propel the growth of the extended-release drugs market going forward. The pharmaceutical industry is a sector of the healthcare industry that focuses on the discovery, development, production, and marketing of drugs and medications. Extended-release drugs contribute to improved patient compliance, enhanced therapeutic outcomes, reduced frequency of administration, steady drug levels in the bloodstream, minimized side effects, reduced fluctuations in symptoms and a better overall pharmaceutical experience. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade association representing the pharmaceutical industry, the total pharmaceutical production in Europe accounted for $384,200 million (€340,000 million) in 2022, with an increase of approximately 4.95% from 366,267 million (€323,950 million) in 2021. Therefore, the increasing demand for pharmaceutical industry is driving the growth of the extended-release drugs industry.

Who Are The Major Players In The Global Extended-Release Drugs Market?

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

What Are The Key Trends Of The Global Extended-Release Drugs Market? Pioneer In Epilepsy Treatment Innovation

Product innovation is a key trend gaining popularity in the extended-release drug market. Major companies operating in the extended-release drug market are developing innovative products to sustain their position in the market. For instance, in July 2022, Zydus Pharmaceuticals (USA) Inc., a US-based generic pharmaceutical manufacturer, launched Topiramate extended-release capsules for epilepsy. The US Food and Drug Administration (USFDA) has previously approved the company to commercialize Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. It is the first business in the country to obtain final approval and introduce Topiramate extended-release capsules. Topiramate extended-release tablets are approved in two ways for individuals with partial onset or primary generalized tonic-clinic seizure.

What Are The Key Trends Of The Global Extended-Release Drugs Market? Extended-Release Tablets For Enhanced Treatment Of Huntington Disease-Related Movement Disorders

Major companies operating in the extended-release drugs market are developing innovative products such as next-generation extended-release tablets to enhance product offerings and gain a competitive advantage. Extended-release tablets are a type of pharmaceutical formulation designed to release their active ingredients gradually over an extended period. For instance, in February 2023, Teva Pharmaceutical Industries Ltd. an Israel-based pharmaceutical company received approval from the U.S. Food and Drug Administration (FDA) for austedo XR (deutetrabenazine). Austedo XR is recommended for the treatment of adults with chorea and tardive dyskinesia related to Huntington disease. They come in dosages of 6, 12, and 24 mg. With the approval of austedo XR, patients with tardive dyskinesia and Huntington disease chorea now have another efficient treatment option. This allows individuals to live with these disorders and the medication is administered once daily. The development of austedo XR, which provides a practical and efficient therapeutic alternative for those with certain movement disorders, signifies a significant leap in the management of these ailments.

Need data on a specific region in this market?
Request Customisation

Extended-Release Drugs Market Merger And Acquisition: Pfizer Expands Portfolio Through Acquisition Of Arena Pharmaceuticals

In March 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology corporation, acquired Arena Pharmaceuticals for approximately $6.7 billion. With this acquisition, Pfizer gains access to various exciting and promising development-stage pharmaceutical prospects from Arena Pharmaceuticals in cardiology, dermatology, and gastroenterology. Arena Pharmaceuticals is a US-based biopharmaceutical company with small-molecule extended-release medications under development for potential clinical use in various therapeutic fields.

Regional Outlook For The Global Extended-Release Drugs Market

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Extended-Release Drugs Market?

The extended-release drug market consists of sales of extended-release tablets, extended-release capsules, and implants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Extended-Release Drugs Industry?

The extended-release drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the extended-release drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Extended-Release Drugs Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $69.63 billion
Revenue Forecast In 2034 $111.26 billion
Growth Rate CAGR of 12.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores Subsegments: 1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Extended-Release Drugs Market Characteristics

3. Extended-Release Drugs Market Trends And Strategies

4. Extended-Release Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Extended-Release Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Extended-Release Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Extended-Release Drugs Market Growth Rate Analysis

5.4. Global Extended-Release Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Extended-Release Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Extended-Release Drugs Total Addressable Market (TAM)

6. Extended-Release Drugs Market Segmentation

6.1. Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Sustained Release Drug

Controlled Release Drug

6.2. Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Over-The-Counter

Prescription

6.3. Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Mail Order Pharmacies

Drug Stores

6.4. Global Extended-Release Drugs Market, Sub-Segmentation Of Sustained Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Matrix Systems

Coating Systems

6.5. Global Extended-Release Drugs Market, Sub-Segmentation Of Controlled Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Osmotic Systems

Microencapsulation Systems

Targeted Delivery Systems

7. Extended-Release Drugs Market Regional And Country Analysis

7.1. Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Extended-Release Drugs Market

8.1. Asia-Pacific Extended-Release Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Extended-Release Drugs Market

9.1. China Extended-Release Drugs Market Overview

9.2. China Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Extended-Release Drugs Market

10.1. India Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Extended-Release Drugs Market

11.1. Japan Extended-Release Drugs Market Overview

11.2. Japan Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Extended-Release Drugs Market

12.1. Australia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Extended-Release Drugs Market

13.1. Indonesia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Extended-Release Drugs Market

14.1. South Korea Extended-Release Drugs Market Overview

14.2. South Korea Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Extended-Release Drugs Market

15.1. Western Europe Extended-Release Drugs Market Overview

15.2. Western Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Extended-Release Drugs Market

16.1. UK Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Extended-Release Drugs Market

17.1. Germany Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Extended-Release Drugs Market

18.1. France Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Extended-Release Drugs Market

19.1. Italy Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Extended-Release Drugs Market

20.1. Spain Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Extended-Release Drugs Market

21.1. Eastern Europe Extended-Release Drugs Market Overview

21.2. Eastern Europe Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Extended-Release Drugs Market

22.1. Russia Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Extended-Release Drugs Market

23.1. North America Extended-Release Drugs Market Overview

23.2. North America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Extended-Release Drugs Market

24.1. USA Extended-Release Drugs Market Overview

24.2. USA Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Extended-Release Drugs Market

25.1. Canada Extended-Release Drugs Market Overview

25.2. Canada Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Extended-Release Drugs Market

26.1. South America Extended-Release Drugs Market Overview

26.2. South America Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Extended-Release Drugs Market

27.1. Brazil Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Extended-Release Drugs Market

28.1. Middle East Extended-Release Drugs Market Overview

28.2. Middle East Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Extended-Release Drugs Market

29.1. Africa Extended-Release Drugs Market Overview

29.2. Africa Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Extended-Release Drugs Market Competitive Landscape And Company Profiles

30.1. Extended-Release Drugs Market Competitive Landscape

30.2. Extended-Release Drugs Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. GlaxoSmithKline PLC Overview, Products and Services, Strategy and Financial Analysis

31. Extended-Release Drugs Market Other Major And Innovative Companies

31.1. AstraZeneca PLC

31.2. Gilead Sciences Inc.

31.3. Boehringer Ingelheim International GmbH

31.4. Viatris Inc.

31.5. Teva Pharmaceuticals Inc.

31.6. Eastman Chemical Company

31.7. Catalent Pharma Solutions Inc.

31.8. Sun Pharmaceutical Industries Limited

31.9. Purdue Pharma LP

31.10. Amneal Pharmaceuticals Inc.

31.11. Endo Pharmaceuticals Inc.

31.12. Mallinckrodt LLC

31.13. Allergan plc

31.14. Hisamitsu Pharmaceutical Co. Inc.

31.15. Janssen Pharmaceuticals Inc.

32. Global Extended-Release Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Extended-Release Drugs Market

34. Recent Developments In The Extended-Release Drugs Market

35. Extended-Release Drugs Market High Potential Countries, Segments and Strategies

35.1 Extended-Release Drugs Market In 2029 - Countries Offering Most New Opportunities

35.2 Extended-Release Drugs Market In 2029 - Segments Offering Most New Opportunities

35.3 Extended-Release Drugs Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Extended-Release Drugs Market, Sub-Segmentation Of Sustained Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Extended-Release Drugs Market, Sub-Segmentation Of Controlled Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Pfizer Inc. Financial Performance
  • Table 77: AbbVie Inc. Financial Performance
  • Table 78: Novartis AG Financial Performance
  • Table 79: Sanofi S.A. Financial Performance
  • Table 80: GlaxoSmithKline PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Extended-Release Drugs Market, Sub-Segmentation Of Sustained Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Extended-Release Drugs Market, Sub-Segmentation Of Controlled Release Drug, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Extended-Release Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Extended-Release Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Extended-Release Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Extended-Release Drugs Market, Segmentation By Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Extended-Release Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Pfizer Inc. Financial Performance
  • Figure 77: AbbVie Inc. Financial Performance
  • Figure 78: Novartis AG Financial Performance
  • Figure 79: Sanofi S.A. Financial Performance
  • Figure 80: GlaxoSmithKline PLC Financial Performance

Emerging Trends and Growth Drivers in the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Through 2029

Read More About Emerging Trends and Growth Drivers in the Investigational New Drug Contract Development And Manufacturing Organization (CDMO) Market Through 2029

Global Leukemia Inhibitory Factor (LIF) Market Landscape: Trends and Market Share to 2029

Read More About Global Leukemia Inhibitory Factor (LIF) Market Landscape: Trends and Market Share to 2029

2025 Medical Amino Acid Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Read More About 2025 Medical Amino Acid Market Outlook: Opportunities, Growth Trends, and Strategic Analysis

Industry Trends Show Medicated Skincare Market Set to Expand at 6.6% CAGR Until 2029

Read More About Industry Trends Show Medicated Skincare Market Set to Expand at 6.6% CAGR Until 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Read More About Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Hospitality Property Management Software Global Market Report 2025 – By Deployment (On-Premise, Cloud), By Organization Size (Large Enterprises, Small And Medium Enterprises), By Application (Business Hotels, Resorts And...

View Report

Mango Global Market Report 2025 – By Type (Whole Fruit, Mango Pulp And Puree, Processed Mango Products), By Nature (Conventional, Organic), By Packaging Type (Bag, Pouches, Tray, Box, Other Packaging Types), By Distribut...

View Report

Aerospace Valves Global Market Report 2025 - By Type (Butterfly Valves, Rotary Valves, Solenoid Valves, Flapper-nozzle Valves, Poppet Valves, Gate Valves, Ball Valves, Other Types), By Material (Stainless Steel, Titanium...

View Report

Drug Delivery Devices Global Market Report 2025 – By Route Of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Trans...

View Report

Drug Delivery Devices Global Market Report 2025 – By Route Of Administration (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ocular Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Trans...

View Report

Injectable Drug Delivery Devices Global Market Report 2025 – By Type (Syringes, Injectors And Pump), By Application (Autoimmune Diseases, Hormonal Disorders, Oncology, Orphan Diseases, Pain Management, Respiratory Therap...

View Report

Automotive Roof System Global Market Report 2025 – By Type (Sunroof System, Panorama Roof System, Multi-Optional Roof System, Solar Roof System, Light Weight Roof System, Inbuilt Roof System, Other Types), By Material (A...

View Report

Basal Cell Carcinoma Treatment Global Market Report 2025 – By Treatment (Surgery, Medication, Other Treatments), By Route Of Administration (Oral, Parenteral, Other Route Of Administrations), By Distribution Channel (Hos...

View Report

Frequently Asked Questions

Extended-release drugs are a dosage form made to release the medication over a longer time, at a predetermined rate, duration, and location, in a controlled manner. The drug can be taken less frequently than the immediate release form, and patients may take 1 to 2 doses each day instead of 3 to 4. For further insights on this market, request a sample here

The market major growth driver - Rising Chronic Conditions Is A Catalyst For Growth In The Extended-Release Drug Market. For further insights on this market, request a sample here

The extended-release drugs market size has grown rapidly in recent years. It will grow from $63.11 billion in 2024 to $69.63 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to patient compliance improvement, chronic disease prevalence, improved efficacy, patent protection strategy, biodegradable implants The extended-release drugs market size is expected to see rapid growth in the next few years. It will grow to " $111.26 billion in 2029 at a compound annual growth rate (CAGR) of 12.4%. The growth in the forecast period can be attributed to personalized medicine approaches, patient-centric drug development, rising incidence of lifestyle diseases, drug repurposing, global access to extended-release therapies. Major trends in the forecast period include pharmaceutical innovation, advancements in drug delivery systems, advancements in nanotechnology, 3d printing in drug formulations, use of artificial intelligence, environmental sustainability. For further insights on this market, request a sample here

The extended-release drugs market covered in this report is segmented –
1) By Type: Sustained Release Drug, Controlled Release Drug
2) By Mode: Over-The-Counter, Prescription
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores Subsegments:
1) By Sustained Release Drug: Matrix Systems, Coating Systems
2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems For further insights on this market, request a sample here

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc. . For further insights on this market, request a sample here.

Major trends in this market include Pioneer In Epilepsy Treatment Innovation. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Extended-Release Drugs Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon